BLTE

Belite Bio, Inc

A clinical-stage biopharmaceutical company developing an oral pill, tinlarebant, meant to slow vision loss in inherited retinal diseases like Stargardt disease and geographic atrophy. Founded by Dr. Tom Lin, it grew out of his earlier drug company Lin BioScience and went public on the Nasdaq in 2022, with headquarters in San Diego. Its name is often read as a nod to its mission of helping people "be light" by protecting their sight.

Sponsored American Depositary Shares

No proxy statement recorded.